Plain-English translation of NCT06217822 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study testing a new medication called 225Ac-PSMA-Trillium (also called BAY3563254) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The medication works by delivering radiation directly to cancer cells, which may help shrink tumors or slow their growth. Researchers are looking to find the safest and most effective dose, and to see how well this treatment works for different groups of patients.
Advanced prostate cancer that no longer responds to hormone therapy is very difficult to treat, and patients need new options. This medication is designed to target cancer cells more precisely by using a radioactive particle that homes in on a specific protein found on prostate cancer cells, potentially offering a new way to control the disease.
You likely qualify if…
You likely don't qualify if…
Participants will come to the research center to receive doses of the new medication, which is given as an injection. The study has two parts: first, researchers will gradually increase the dose in small groups of patients to find the safest level; then, they will test that dose in larger groups of patients with different treatment histories. Throughout the study, you will have regular blood tests, imaging scans, and follow-up visits so doctors can monitor how the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States
Belgium
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.